Key result
Statins cut cardiotoxicity risk ~54% in cancer patients receiving anthracyclines or trastuzumab.
Why the study?
Cardiotoxicity affects 5-16% of cancer patients receiving anthracyclines and/or trastuzumab, but limited research has examined interventions to mitigate this cardiotoxicity.
Does statin use lower the risk of cardiotoxicity among cancer survivors treated with anthracyclines and/or trastuzumab?
Meta-Analysis (n=930)
Does statin use lower the risk of cardiotoxicity among cancer survivors treated with anthracyclines and/or trastuzumab?
Effect estimate: RR 0.46 (95% CI 0.27-0.78)
p-value: p=0.004
Statin use during anthracycline and/or trastuzumab therapy is associated with a significantly lower risk of cardiotoxicity in observational studies and better preservation of left ventricular ejection fraction across both observational and randomized trials.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Anthracycline-induced cardiotoxicity is a major contributor to long-term cardiovascular (CV) outcomes in survivors of cancer. Up to 20% of patients exposed to anthracyclines develop irreversible cardiomyopathy through mechanisms leading to cardiomyocyte death.”
Statin use may mitigate cardiotoxicity in anthracycline/trastuzumab recipients; leaves open confirmation in randomized trials.
Obasi et al. (2021) conducted a meta-analysis in Cancer treated with anthracyclines and/or trastuzumab (n=930). Statins vs. No statin or placebo was evaluated on Incidence of cardiotoxicity (RR 0.46, 95% CI 0.27-0.78, p=0.004). Statin use significantly reduced the risk of cardiotoxicity by 54% (RR 0.46) compared to no statin use in cohort studies of cancer patients treated with anthracyclines and/or trastuzumab.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: